Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3M has revealed that, according to a recent study published in the June issue of Dermatologic Surgery, its prescription Aldara cream 5% delivers long-term clinical benefits in the treatment of actinic keratosis, a precancerous skin condition caused by chronic sun exposure.
Subscribe to our email newsletter
Led by an investigator at the University of Minnesota, the study showed 75% of patients treated with Aldara Cream three times per week, and nearly 60% treated two times per week, continued to demonstrate complete clearance of actinic keratosis after a follow-up period of 12 to 18 months.
“This study confirms my belief in Aldara cream and its potential to proactively treat certain types of actinic keratosis and, more importantly, decrease the possibility for recurrence,” said Dr Peter Lee, lead investigator, University of Minnesota.
Dr Lee also noted that treatment with Aldara cream for both clinical and subclinical actinic keratosis lesions could reduce the number of physician visits and treatments, as well as the potential for developing squamous cell carcinoma.
The first immune response modifier approved for actinic keratosis, Aldara cream stimulates the skin’s immune response, which may help decrease formation of recurrent or new actinic keratosis.